Insider Selling: Tango Therapeutics, Inc. (NASDAQ:TNGX) Insider Sells 4,288 Shares of Stock

Tango Therapeutics, Inc. (NASDAQ:TNGXGet Free Report) insider Adam Crystal sold 4,288 shares of Tango Therapeutics stock in a transaction on Tuesday, February 6th. The stock was sold at an average price of $12.56, for a total value of $53,857.28. Following the sale, the insider now directly owns 123,561 shares of the company’s stock, valued at $1,551,926.16. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website.

Tango Therapeutics Price Performance

Shares of Tango Therapeutics stock opened at $12.41 on Friday. The firm has a market cap of $1.27 billion, a price-to-earnings ratio of -11.18 and a beta of 0.95. The stock’s 50-day moving average is $10.57 and its 200-day moving average is $8.62. Tango Therapeutics, Inc. has a one year low of $2.47 and a one year high of $13.03.

Tango Therapeutics (NASDAQ:TNGXGet Free Report) last issued its quarterly earnings results on Wednesday, November 8th. The company reported ($0.23) EPS for the quarter, beating analysts’ consensus estimates of ($0.34) by $0.11. Tango Therapeutics had a negative return on equity of 41.41% and a negative net margin of 266.73%. The company had revenue of $10.73 million for the quarter, compared to analyst estimates of $8.05 million. On average, equities analysts expect that Tango Therapeutics, Inc. will post -1.07 EPS for the current year.

Wall Street Analyst Weigh In

Separately, B. Riley began coverage on Tango Therapeutics in a research note on Friday, December 8th. They set a “buy” rating and a $16.00 price objective for the company.

Read Our Latest Stock Report on TNGX

Institutional Trading of Tango Therapeutics

Institutional investors and hedge funds have recently bought and sold shares of the stock. Allspring Global Investments Holdings LLC bought a new stake in Tango Therapeutics during the second quarter worth about $48,000. Strs Ohio raised its holdings in Tango Therapeutics by 71.9% during the third quarter. Strs Ohio now owns 23,900 shares of the company’s stock worth $269,000 after acquiring an additional 10,000 shares in the last quarter. SG Americas Securities LLC bought a new stake in Tango Therapeutics during the third quarter worth about $233,000. L2 Asset Management LLC bought a new stake in Tango Therapeutics in the third quarter valued at approximately $185,000. Finally, Bank of New York Mellon Corp raised its stake in Tango Therapeutics by 9.5% in the third quarter. Bank of New York Mellon Corp now owns 154,673 shares of the company’s stock valued at $1,742,000 after buying an additional 13,418 shares during the period. Institutional investors own 78.99% of the company’s stock.

About Tango Therapeutics

(Get Free Report)

Tango Therapeutics, Inc, a biotechnology company, discovers and develops drugs for the treatment of cancer. Its lead program is TNG908, a synthetic lethal small molecule inhibitor of protein arginine methyltransferase 5 that is being developed as a treatment for cancers with methylthioadenosine phosphorylase deletions.

Further Reading

Insider Buying and Selling by Quarter for Tango Therapeutics (NASDAQ:TNGX)

Receive News & Ratings for Tango Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Tango Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.